You’ll be able to examine this (or watch the video) at varied locations. One is TheFocalPoints.com.
“84.four% of Most cancers Sufferers Taking Ivermectin + Mebendazole Reported No Proof of Illness, Tumor Regression, or Most cancers Stabilization After 6 Months”
It simply sounds too good to be true. And you recognize need that normally means. I’ve not carried out a deep dive into this report however I’m very skeptical. The examine lumped a bunch of various most cancers varieties collectively: breast, pancreas, colon, lung, and so on. The uneducated amongst us might imagine all cancers are alike. They aren’t. They behave in a different way and, historically, require totally different therapeutic approaches for one of the best end result. If (and that’s an enormous IF) there’s a unifying underlying chemical or mobile phenomenon that causes all cancers, then a panacea like ivermectin/mebendazole could also be an efficient therapy. (In case you’re questioning, I used to be ready to take ivermectin in the course of the pandemic however by no means did.)
Only a reminder, I’m not a most cancers specialist. If I had most cancers, I’d seek the advice of a most cancers specialist, usually an oncologist.
Authors of the examine at hand do observe that “…these findings ought to be interpreted as hypothesis-generating. Pressing potential, randomized, placebo-controlled scientific trials are warranted to validate these observations and additional outline optimum dosing methods.” It’s possible you’ll acknowledge one of many authors, TV superstar Dr. Drew Pinsky. What a Renaissance man! Different acquainted creator names are Peter McCullough and Harvey Risch.
Dr. David Weinberg at Science Based mostly Medication has carried out a deep dive and concluded:
It is a shoddy analysis examine offered as a high quality enchancment undertaking. This doubtful classification functioned as an excuse for lack of interface with related regulatory our bodies.
There may be validity to the assertion that ivermectin and mebendazole present anticancer exercise in preclinical research. This examine supplies no significant proof for or in opposition to the efficacy of such therapies in people with most cancers.
—–Steve Parker, M.D.
